Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Drug Policy / Regulatory

China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Apr 17, 2024

The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...

Company Drug

AstraZeneca’s Imfinzi Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer Trial

Fineline Cube Apr 17, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has this week announced 3-year...

Medical Device Policy / Regulatory

China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan

Fineline Cube Apr 17, 2024

The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision...

Company Deals

Beijing Airdoc Leads RMB 500 Million Joint Venture to Invest in AI-Powered Healthcare

Fineline Cube Apr 17, 2024

Beijing Airdoc Technology Co., Ltd., a leading artificial intelligence (AI)-powered ophthalmology device company, has announced...

Company Drug

Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment

Fineline Cube Apr 17, 2024

Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of...

Company Drug

China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment

Fineline Cube Apr 17, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval...

Company

Roche China’s Talent and Culture Vice President Chen Yanli Departs for New Opportunities

Fineline Cube Apr 16, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced the departure of Chen Yanli, who...

Company Drug

Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor

Fineline Cube Apr 16, 2024

Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...

Company Drug

Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers

Fineline Cube Apr 16, 2024

Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a...

Company Drug

Roche’s Columvi Meets Overall Survival Endpoint in Diffuse Large B-Cell Lymphoma Trial

Fineline Cube Apr 16, 2024

Roche (SWX: RO), a leading Swiss pharmaceutical company, has announced that a late-stage clinical trial...

Company Drug

Novartis’s Fabhalta Shows Promise in Phase III IgA Nephropathy Trial

Fineline Cube Apr 16, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive preliminary results from a Phase III...

Policy / Regulatory

EU Set to Investigate China’s Medical Device Procurement Practices Amid Fairness Concerns

Fineline Cube Apr 16, 2024

The European Union (EU) is reportedly gearing up to launch an investigation into medical device...

Company Deals

Ningbo Menovo Partners with University of Michigan to Develop GLP-1 Delivery System

Fineline Cube Apr 16, 2024

Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538), a China-based company, has announced a strategic partnership...

Company Deals Digital

Vazyme Partners with Yufang Medical to Boost Alzheimer’s Blood Test Sales Online

Fineline Cube Apr 16, 2024

Vazyme Biotech Co., Ltd (SHA: 688105), based in China, has entered into a strategic partnership...

Company Drug

Keymed Biosciences Achieves First Dosing in Global Phase III Trial for Claudin 18.2 Targeting ADC

Fineline Cube Apr 15, 2024

Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced the completion...

Company Deals

89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China

Fineline Cube Apr 15, 2024

U.S. biotechnology company 89bio (NASDAQ: ETNB) has secured the services of China-based Contract Development and...

Company Medical Device

Shanghai Electric Group and Siemens Healthineers Unveil Ultramarine Series Medical Imaging Devices

Fineline Cube Apr 15, 2024

Shanghai Electric Group, a major player in China’s electrical equipment industry, has partnered with Siemens...

Company Deals Digital

JD Healthcare Forges Partnerships with Top Medical Device Firms at CMEF

Fineline Cube Apr 15, 2024

The China International Medical Equipment Fair (CMEF), which took place last week in Shanghai, was...

Policy / Regulatory

FDA Advisory Committee Backs MRD as Accelerated Approval Endpoint for Multiple Myeloma

Fineline Cube Apr 15, 2024

The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) has...

Company

I-Mab CEO Outlines Streamlined US Entity’s Focus and Potential for In-Licensing

Fineline Cube Apr 15, 2024

I-Mab (NASDAQ: IMAB), a biopharmaceutical company that recently restructured into separate US and Chinese entities,...

Posts pagination

1 … 321 322 323 … 613

Recent updates

  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
  • Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio
  • TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China
  • China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.